VRV. V. Radovsky

V. V. Radovsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. V. Radovsky has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    H. pylori infection in gastrointestinal cancer: impact on the development, prognosis, and effectiveness of anticancer therapy. Literature review

    by M. I. Makarova, I. S. Shumskaya, E. A. Kolesnikova, N. M. Kiselyov, V. V. Radovsky, S. V. Gamayunov

    Study Objective : to provide an overview of current scientific data on the impact of H. pylori infection and eradication therapy on the development, clinical course and treatment outcomes of gastrointestinal cancer. Material and Methods . A search of Russian and English-language literature sources published in various databases (MedLine, Pubmed, Scopus, The Cochrane Library, and Russian Science Citation Index) between 2004 and 2025 was conducted. Fifty-three available scientific publications were analyzed, including 5 Russian and 48 foreign publications, including 41 articles, 10 meta-analyses, and 2 retrospective studies. Results . An analysis of scientific papers showed that H. pylori infection significantly worsened treatment outcomes and survival in patients with already diagnosed gastric cancer. Literature data demonstrate a positive impact of H. pylori eradication on survival in both early and advanced gastric cancer. In addition to being a major risk factor for stomach cancer, H. pylori infection is also associated with an increased risk of colorectal cancer, esophageal adenocarcinoma, pancreatic cancer, and biliary tract cancer. Furthermore, H. pylori infection impacts the effectiveness of immunotherapy in cancer treatment Conclusion . H. pylori infection and eradication therapy can influence the development and clinical course of gastrointestinal tumors. Despite the close attention of many scientists to this issue, key questions remain poorly understood.

  • Open Access

    Surgical Treatment of Aortic Valve Papillary Fibroelastoma in Combination With Coronary Artery Bypass Grafting

    by S. A. Fedorov, S. A. Zhurko, O. R. Shirokova, V. V. Radovsky

       Objective: To describe a rare case of surgical treatment of aortic valve papillary fibroelastoma in combination with coronary artery bypass grafting.   Clinical case: The patient was hospitalized with a suspected mass on the left coronary cusp of the aortic valve and complained of retrosternal pain that appeared during moderate exertion and brisk walking and went away with rest. The patient history revealed that these clinical manifestations began in February 2022 and were treated by coronary stenting. Since May 2022 the patient noticed symptoms of recurrent angina. Transthoracic echocardiogram dated June 14, 2022 revealed a 13 × 12 mm additional mobile mass on the left coronary cusp. On June 30, 2022 the patient had an open surgery: mass removal, coronary artery bypass grafting of the anterior descending artery, and coronary artery bypass grafting of the circumflex artery. During the aortic valve exploration, the mass was visualized on the left coronary cusp on the side of the left ventricle. The mass was removed by precision marginal excision.   Conclusions: To timely examine patients, refer them for surgical treatment, preserve and prolong their life, and improve its quality, clinical practitioners should know clinical manifestations and challenges in screening for aortic valve papillary fibroelastoma.